Fosaprepitant dimeglumine
Emend, Focinvez, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant dimeglumine) is a small molecule pharmaceutical. Fosaprepitant dimeglumine was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Emend, Focinvez, Fosaprepitant dimeglumine (discontinued: Emend, Fosaprepitant dimeglumine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosaprepitant dimeglumine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMEND | Merck & Co | N-022023 RX | 2010-11-12 | 1 products, RLD, RS |
| FOCINVEZ | SteriScience | N-216686 RX | 2023-08-22 | 1 products, RLD, RS |
| FOSAPREPITANT DIMEGLUMINE | Teva | N-210064 RX | 2019-09-05 | 1 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emend | New Drug Application | 2022-05-04 |
| focinvez | New Drug Application | 2025-06-12 |
| fosaprepitant | ANDA | 2024-12-29 |
| fosaprepitant dimeglumine | ANDA | 2024-08-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC | |||
| 2025-05-02 | D-186 | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
126 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | 8 | 22 | 19 | 18 | 15 | 80 |
| Nausea | D009325 | — | R11.0 | 4 | 21 | 17 | 14 | 16 | 70 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 3 | 4 | 9 | 7 | 24 |
| Neoplasms | D009369 | — | C80 | 3 | 3 | 2 | 2 | 5 | 13 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | 1 | 3 | 6 |
| Leukemia | D007938 | — | C95 | — | 2 | — | 1 | 2 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | 1 | 1 | 1 | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | 1 | 3 | 4 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | 1 | — | 3 |
| Pruritus | D011537 | — | L29 | 1 | 1 | — | 1 | — | 3 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | 9 | — | — | 9 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | — | — | 9 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 9 | — | — | 9 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | 1 | — | 2 | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | 1 | — | 1 | 4 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | 1 | — | 2 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | 1 | 3 |
| Female genital neoplasms | D005833 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | — | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | 1 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | 2 | 3 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | 2 | 3 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | 1 | 2 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Show 20 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
| Heroin dependence | D006556 | EFO_0004240 | — | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 2 | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 2 | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 2 | 2 |
| Plasmacytoma | D010954 | — | C90.3 | — | — | — | — | 2 | 2 |
| Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fosaprepitant dimeglumine |
| INN | aprepitant |
| Description | Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 172673-20-0 |
| RxCUI | 1731071 |
| ChEMBL ID | CHEMBL1201782 |
| ChEBI ID | 64311 |
| PubChem CID | 219090 |
| DrugBank | DB06717 |
| UNII ID | 6L8OF9XRDC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emend – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 95 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,529 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use